ARGOBIO
We fund, incubate breakthrough science and build therapeutics-based biotech companies
Location
- 75015
- PARIS
- France
Description of your activity
-
Argobio is a startup studio with 50 M€ funding dedicated to therapeutic drug development in rare diseases, neurology, autoimmunity, inflammation, and oncology.
We build high-potential biotech companies up to Series A financing, based on disruptive research projects.
Objectives
Financing / investment needs
- Stage of maturity / investment
- Early stage (seed)
- Average ticket sought / investment
- 1 ME to 3 ME
- 3 to 10 ME
- Typology of funder
- Seed Capital
- Venture capital
Fields of application
- Health - Health Technologies
- Health - Pharmacy - Biotechnology
Offer detail
Argobio Studio: Where Innovation Meets Impact
Welcome to our start-up studio, where we're accelerating drug development by bridging the gap between groundbreaking research and life-changing therapies. Our focus? Rare diseases, neurology, autoimmunity, inflammation, and oncology.
What we do ?
Collaborate to innovate: We partner closely with top researchers, unlocking the full potential of their discoveries to accelerate the creation of game-changing treatments.
Funding to fuel success: With up to 5 million euros in financial support, we streamline the development process, ensuring critical resources are in place to fast-track research and reach the clinic sooner.
Sharing our expertise: Our seasoned team of drug developers brings a wealth of knowledge and industry connections to every project, navigating the complex development process with ease and increasing the chances of success.
Supplier
Participants
Oscar CASTANON
Open Innovation Director
Nicolas BILLIALD
Open Innovation Director
Landmarks
- Year of creation :
- Turnover : < 2 M€
- Workforce : 10 - 99
- Company Category :